Methasan

Methadone, the active ingredient in Methasan, is an opioid agonist presented as an oral formulation for oral use. It is employed in the management of opioid dependence and in the treatment of chronic pain, providing analgesia and reducing withdrawal symptoms in adult patients.

GNH USA supplies Methasan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for each batch. Customers benefit from reliable supply chains and responsive technical support.

Methadone acts on the opioid system and is indicated for several opioid‑related conditions. - Opioid dependence treatment: stabilizes patients on a long‑acting opioid, reducing illicit opioid use, cravings, and risk of relapse. - Chronic pain management: provides sustained analgesia for severe, long‑term pain, especially when other opioids are ineffective or not tolerated. - Opioid withdrawal management: alleviates acute withdrawal symptoms during detoxification, enabling a smoother transition to abstinence or maintenance therapy. - Palliative care: contributes to pain control in terminal illness when high‑dose opioid therapy is required.

Methadone may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Constipation: reduced gastrointestinal motility leading to hard stools. - Nausea: feeling of queasiness, sometimes with vomiting. - Drowsiness: increased sleepiness or fatigue. - Sweating: excessive perspiration unrelated to temperature.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that can be life‑threatening. - QT interval prolongation: cardiac electrical disturbance increasing arrhythmia risk. - Severe hypotension: marked drop in blood pressure causing dizziness or fainting. - Allergic reaction: rash, itching, swelling, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Assess patient history: review prior opioid use, tolerance, and risk factors for dependence. - Monitor respiratory function: observe for signs of respiratory depression, especially during dose titration. - Evaluate cardiac status: obtain baseline ECG to detect QT prolongation risk. - Use lowest effective dose: titrate cautiously to balance analgesia with safety. - Avoid use in severe hepatic impairment: impaired metabolism may increase toxicity. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Methadone can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may cause toxic methadone levels. - Other CNS depressants (e.g., benzodiazepines): increase risk of respiratory depression.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may reduce methadone effectiveness. - QT‑prolonging drugs (e.g., macrolide antibiotics): additive cardiac risk. - Alcohol: potentiates sedative effects and may worsen respiratory depression.